Symphogen moves new candidate into clinical phases
The biotech company has taken another step toward the big leagues by sending its second candidate drug into clinical phases. The drug combines two antibodies and will target a number of different cancer types.
BY LOUISE WENDT JENSEN
“The more products you have in clinical phases, the better it is for the company,” Kirsten Drejer, CEO of Symphogen, tells MedWatch after the biotech company announced that it would be initiating clinical trials with a second candidate drug.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
